Related references
Note: Only part of the references are listed.The evolution of bispecific antibodies
Nimish Gera
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
NCATS Inxight Drugs: a comprehensive and curated portal for translational research
Vishal B. Siramshetty et al.
NUCLEIC ACIDS RESEARCH (2022)
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
Sofia S. Guimaraes Koch et al.
MABS (2022)
Antibody markup language (AbML) - a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)
James Sweet-Jones et al.
MABS (2022)
New INN nomenclature for monoclonal antibodies
Raffaella Balocco et al.
LANCET (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Thera-SAbDab: the Therapeutic Structural Antibody Database
Matthew I. J. Raybould et al.
NUCLEIC ACIDS RESEARCH (2020)
R409K mutation prevents acid-induced aggregation of human IgG4
Hiroshi Namisaki et al.
PLOS ONE (2020)
Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies
Steffen Dickopf et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment
Rena Liu et al.
ANTIBODIES (2020)
L445P mutation on heavy chain stabilizes IgG4 under acidic conditions
Chang-Ai Xu et al.
MABS (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Kevin O. Saunders
FRONTIERS IN IMMUNOLOGY (2019)
Current progress in innovative engineered antibodies
William R. Strohl
PROTEIN & CELL (2018)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
Chunpeng Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Peter Ulrichts et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
The ChEMBL database in 2017
Anna Gaulton et al.
NUCLEIC ACIDS RESEARCH (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more
Paul W. H. I. Parren et al.
MABS (2017)
The INNs and outs of antibody nonproprietary names
Tim D. Jones et al.
MABS (2016)
KEGG as a reference resource for gene and protein annotation
Minoru Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2016)
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Julia Stieglmaier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Targeting FcRn for the modulation of antibody dynamics
E. Sally Ward et al.
MOLECULAR IMMUNOLOGY (2015)
Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
Scot D. Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cell Contact-Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response
Patrick Bartholomaeus et al.
JOURNAL OF IMMUNOLOGY (2014)
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S. Kung Sutherland et al.
BLOOD (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Pavel Strop et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength
Aran F. Labrijn et al.
JOURNAL OF IMMUNOLOGY (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
Marijn van der Neut Kolfschoten et al.
SCIENCE (2007)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
In vitro characterization of five humanized OKT3 effector function variant antibodies
DL Xu et al.
CELLULAR IMMUNOLOGY (2000)
Share Paper
